# Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine

> **NCT06831812** · PHASE1 · COMPLETED · sponsor: **Nuravax, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Alzheimer Disease
- Alzheimer Disease (AD)
- Alzheimers Disease Prevention

## Interventions

- **BIOLOGICAL:** AV-1959R (Abeta vaccine)

## Key facts

- **NCT ID:** NCT06831812
- **Lead sponsor:** Nuravax, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-12
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06831812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06831812, "Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06831812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*